Related Experiment Videos
Immunotherapy for Epstein-Barr virus-associated tumors
Melanie A Comito1, Qi Sun, Kenneth G Lucas
1Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Penn State Children's Hospital, Hershey 17033, USA.
Leukemia & Lymphoma
|September 17, 2004
Summary
Epstein-Barr Virus (EBV) drives various cancers, particularly in transplant recipients. Adoptive immunotherapy using EBV-specific T cells shows promise for treating these EBV-associated malignancies.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Epstein-Barr Virus (EBV) is linked to several cancers, including lymphomas in transplant recipients, AIDS-related lymphomas, Burkitt's lymphoma, nasopharyngeal carcinoma (NPC), and Hodgkin's disease (HD).
- The specific type of latent EBV infection influences tumor cell immunogenicity by altering EBV antigen expression.
- While some EBV-associated malignancies stem from impaired immunity (e.g., lymphoproliferations in immunocompromised individuals), others have complex pathogenesis.
Purpose of the Study:
- To review the pathogenesis of EBV-associated malignancies.
- To discuss current therapeutic strategies for these cancers.
- To explore future research directions targeting EBV antigen expression.
Main Methods:
- Review of existing literature on EBV-associated tumors, their pathogenesis, and treatment modalities.
- Analysis of the role of cellular immunity and EBV antigen expression in tumor development and immunogenicity.
- Evaluation of current and emerging therapeutic approaches, including adoptive immunotherapy.
Main Results:
- Restoration of cellular immunity is effective for EBV-driven lymphoproliferations in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.
- Conventional treatments like chemotherapy, radiation, and anti-B cell monoclonal antibodies are used.
- Adoptive transfer of EBV-specific cytotoxic T lymphocytes (CTLs) has shown initial success in SOT and HSCT patients, prompting further investigation for other EBV-associated cancers.
Conclusions:
- EBV-associated malignancies represent a diverse group of cancers with varying links to immune status and distinct EBV antigen expression profiles.
- While conventional therapies exist, adoptive immunotherapy targeting EBV antigens is a promising strategy, particularly for immunocompromised patients and potentially for NPC and HD.
- Further research is crucial to optimize adoptive T-cell transfer and other targeted therapies for improved outcomes in EBV-driven cancers.